Stoke Therapeutics Statistics
Share Statistics
Stoke Therapeutics has 52.97M shares outstanding. The number of shares has increased by 14.39% in one year.
| Shares Outstanding | 52.97M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.61% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 43.07M |
| Failed to Deliver (FTD) Shares | 38 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 7.26M, so 13.7% of the outstanding shares have been sold short.
| Short Interest | 7.26M |
| Short % of Shares Out | 13.7% |
| Short % of Float | 17.65% |
| Short Ratio (days to cover) | 11.35 |
Valuation Ratios
The PE ratio is -2.21 and the forward PE ratio is -5.67.
| PE Ratio | -2.21 |
| Forward PE | -5.67 |
| PS Ratio | 26.36 |
| Forward PS | 19.7 |
| PB Ratio | 1.45 |
| P/FCF Ratio | -2.8 |
| PEG Ratio | n/a |
Enterprise Valuation
Stoke Therapeutics Inc. has an Enterprise Value (EV) of 46.81M.
| EV / Earnings | -0.45 |
| EV / Sales | 5.33 |
| EV / EBITDA | -0.42 |
| EV / EBIT | -0.41 |
| EV / FCF | -0.57 |
Financial Position
The company has a current ratio of 6.99, with a Debt / Equity ratio of 0.
| Current Ratio | 6.99 |
| Quick Ratio | 6.99 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.2 |
| Cash Flow / Debt | -248.67 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.66% and return on capital (ROIC) is -71.01%.
| Return on Equity (ROE) | -0.66% |
| Return on Assets (ROA) | -0.46% |
| Return on Capital (ROIC) | -71.01% |
| Revenue Per Employee | 79.82K |
| Profits Per Employee | -951.81K |
| Employee Count | 110 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 73.35% in the last 52 weeks. The beta is 0.95, so Stoke Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | 73.35% |
| 50-Day Moving Average | 11.9 |
| 200-Day Moving Average | 13.18 |
| Relative Strength Index (RSI) | 26.2 |
| Average Volume (20 Days) | 624.55K |
Income Statement
In the last 12 months, Stoke Therapeutics had revenue of 8.78M and earned -104.70M in profits. Earnings per share was -2.38.
| Revenue | 8.78M |
| Gross Profit | 8.78M |
| Operating Income | -114.77M |
| Net Income | -104.70M |
| EBITDA | -112.30M |
| EBIT | -114.77M |
| Earnings Per Share (EPS) | -2.38 |
Balance Sheet
The company has 191.44M in cash and 2.06M in debt, giving a net cash position of 189.38M.
| Cash & Cash Equivalents | 191.44M |
| Total Debt | 2.06M |
| Net Cash | 189.38M |
| Retained Earnings | -401.85M |
| Total Assets | 293.32M |
| Working Capital | 203.75M |
Cash Flow
In the last 12 months, operating cash flow was -81.07M and capital expenditures -1.62M, giving a free cash flow of -82.68M.
| Operating Cash Flow | -81.07M |
| Capital Expenditures | -1.62M |
| Free Cash Flow | -82.68M |
| FCF Per Share | -1.88 |
Margins
Gross margin is 100%, with operating and profit margins of -1.31K% and -1.19K%.
| Gross Margin | 100% |
| Operating Margin | -1.31K% |
| Pretax Margin | -1.19K% |
| Profit Margin | -1.19K% |
| EBITDA Margin | -1.28K% |
| EBIT Margin | -1.31K% |
| FCF Margin | -941.72% |
Dividends & Yields
STOK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -27.51% |
| FCF Yield | -18.05% |
Analyst Forecast
The average price target for STOK is $20, which is 131.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 131.2% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 2.98 |
| Piotroski F-Score | 3 |